|Day Low/High||0.86 / 0.92|
|52 Wk Low/High||0.60 / 2.30|
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Investors in Cell Therapeutics, Inc. saw new options become available this week, for the January 2016 expiration.
Trade-Ideas LLC identified Cell Therapeutics (CTIC) as a "perilous reversal" (up big yesterday but down big today) candidate
Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.
The drug companies on this list issued the most ridiculous, stock-touting press releases, all seeking to glom onto the excitement of the JPM healthcare conference.
It's still pre-dawn in San Francisco, a few hours from the start of the J.P. Morgan Healthcare Conference, but that hasn't stopped biotech and drug companies from dumping a ton of news and announcements into the market. Here's a brief look at what's making headlines this morning:
Trade-Ideas LLC identified Cell Therapeutics (CTIC) as a pre-market mover with heavy volume candidate
James Dennin, Kapitall: We decided to look for small cap stocks under 5 dollars that may benefit from just the [...]
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Investors in Cell Therapeutics, Inc. saw new options begin trading this week, for the June 2014 expiration.
Cell Therapeutics's shares are rising on the promise made by CEO Jim Bianco to land a pacritinib partner by year's end.
Investors in Cell Therapeutics, Inc. saw new options begin trading this week, for the November 16th expiration.
Cell Therapeutics has lost 99.99 percent of its value in the last dozen years.
Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.
TheStreet's Adam Feuerstein gazes into his crystal ball to offer his 2013 biotech stock forecast.
Cell Therapeutics' Jim Bianco Wins! Amarin CEO Joe Zakrzewski tries to steal election with last-minute plot.
Readers get to decide which of the CEOs from BioSante, BioCryst, Peregrine or Cell Therapeutics deserve the dishonor.
The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.
More data will help Peregrine convince skeptics that bavituximab is a real lung cancer drug.
Cell Therapeutics' CEO Hosts Annual Shareholder Meeting (Transcript)
Check out the accuracy of the 2012 biotech sector predictions made by Adam Feuerstein
Cell Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript
The purchase of another cancer drug is another excuse to raise more money and to pay lavish executive salaries.
David Bests Bruce; Bianco's Bunk; RadioShack's Reflections; STOCK Act Silliness; Cali's Latest Crisis.
Cell Therapeutics suffers another drug development setback and hurts shareholders yet again.
The FDA will issue approval decisions on 17 drugs over the next four months. How well can you predict which drugs will be approved or rejected?
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.